As a key part of Nexion's founding team, Brad brings over 28 years of experience in the field of business development with a passion for moving business concepts and technology to commercial application. Brad has extensive expertise in seed business start-up and growth, strategic planning, and research management. He is a proven driver of company revenue and in negotiating game changing deals with major institutions globally. Brad has traveled to and transacted business on every continent and he has a deep understanding of the business processes and cultural etiquette within and across key countries. Prior to joining Nexion, Mr. White was a founding Partner of Alpha Financial Technologies (AFT) where he co-created the world’s first publicly traded suite of commodity indexes. While acting as Global Head of Business Development during his 13 year tenure with AFT, his company reached peak index assets (AUM) of over $13 Billion.
He holds his Bachelors of Business Administration from The University of Texas and Master of Arts, Legal Studies from Arizona State University.
Chief Executive Officer
Dr. Yates co-founded Nexion and is Chairman of the Board. His research is currently funded by the National Cancer Institute (NCI) and Department of Defense (DOD) Congressionally Medical Directed Research Programs. Dr. Yates is also scientist at Tuskegee University, focused on identifying molecular targets for therapeutic intervention in prostate, breast, and pancreatic cancers. Dr. Yates received his initial training at the University of Pittsburgh School of Medicine in department of Cellular and Molecular Pathology. He completed additional training in Tissue Engineering and Regenerative Medicine jointly from the McGowan Institute for Regenerative Medicine and Massachusetts Institute of Technology (MIT). Dr. Yates completed his post-doctoral training at Emory University School of Medicine in the Department of Molecular Urology.
Chief Scientific Officer
CLAYTON C. YATES Ph.D.
Dr. Jaynes is a Co-Founder and Board Member for Nexion. He leads the research for Nexion and manages ongoing, critical communication with our outside research and development partners and associations. Dr. Jaynes is one of the world's leading authorities on therapeutic peptide design and has vast experience in drug development for various applications, including agriculture, animal health, wound healing, and oncology. Dr. Jaynes’ research is funded by USDA, NSF, and NIH. He has more than 60 United States and foreign patents and has authored over 100 scientific journal articles. Over the past 15 years, Dr. Jaynes has served on the board of numerous life science companies and is currently the Chief Technology Officer for the National Cancer Coalition. Dr. Jaynes is a Professor of Biochemistry at Tuskegee University. Dr. Jaynes completed his doctoral training at Brigham Young University, Utah.
Chief Research Officer
JESSE JAYNES Ph.D.
Dr. Dean-Colomb is a Board Member and is a medical oncologist and physician-scientist. She also has board certification from the American Board of Internal Medicine and is a practicing physician in Louisiana. Dr. Dean-Colomb conducts research across an array of molecular structures affecting all living organisms, as well as has an active research program focused on understanding the metabolism profile of women with triple-negative breast cancer. Dr. Dean-Colomb earned her Doctor of Medicine Degree and PhD in Toxicology from the University of Illinois in Urbana, IL and completed her Oncology fellowship at M.D. Anderson Cancer Center in Houston, Tx.
Chief Clinical Officer
WINDY DEAN-COLOMB MD-PhD
Mr. Harper has over 20 years of experience in the Aerospace and defense industry. His current role at Lockheed Martin is in the Technology Strategy and Innovation Department working under the direction of the Corporate Engineering and Technology Office as the Innovation Manager. He is responsible for executing and managing our enterprise Research and Development (R&D) programs and supporting technology roadmap development, enterprise technology strategy, identifying cross BA technology gaps and transitioning all emerging technologies back to Lockheed Martin’s five business areas. While in this role Mr. Harper as successfully Transitioned multiple programs valued over $1 Billion in DoD contracts. Other key roles also include Future Enterprise Program Lead for Human Augmentation and member of the Intellectual Property/Patent review Board.